AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00866749
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Trial: NCT00866749
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 by vein in weeks 1, 2 and 3
Trial: NCT00564824
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg tablet
Trial: NCT00564824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills
Trial: NCT03184324
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03184324
Drug: DWP14012 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT05037812
Drug: Multimodal injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection).
Trial: NCT00611871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg placebo, followed 2 hrs after with 60mg placebo
Trial: NCT01362595
Drug: leucine
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day
Trial: NCT03946670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is being administered i.v.
Trial: NCT03946670
Drug: Hypomethylating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
Trial: NCT02540720
Drug: Gamma globulin
RxNorm normalized name: Gamma globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00146588
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
Trial: NCT00146588
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
Trial: NCT03574324
Drug: TPF+CCRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy
Trial: NCT04167280
Drug: placebo metered dose inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched MDI to deliver inactive drug
Trial: NCT01099280
Drug: SYNPITAN FORT 5 IU
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
Trial: NCT04564118
Drug: Retrospective analysis of assigned treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: analysis of treatment assigned by physicians within routine clinical practice
Trial: NCT01099280
Drug: Propess,SYNPITAN FORT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
Trial: NCT00674167
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
Trial: NCT02264301
Drug: Qingkailing injection 40 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01637259
Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
RxNorm normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI + PI
Trial: NCT04535167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be formulated for intravenous delivery
Trial: NCT02396069
Drug: JPI-289
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP-1 inhibitor
Trial: NCT02396069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00244166
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04608513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft capsules for oral administration
Trial: NCT01946971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03676959
Drug: ZKAB001 5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/kg/times bi-week IV administration of ZKAB001
Trial: NCT03676959
Drug: ZKAB001 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg/times bi-week IV administration of ZKAB001
Trial: NCT03676959
Drug: ZKAB001 15mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg/times bi-week IV administration of ZKAB001
Trial: NCT04213794
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undergo HIPEC with doxorubicin and cisplatin
Trial: NCT04225039
Drug: INCMGA00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
Trial: NCT04225039
Drug: SRS
RxNorm normalized name: SRS-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
Trial: NCT02916238
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
Trial: NCT03456063
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Trial: NCT02902666
Drug: Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03153410
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle.
Trial: NCT00463268
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo every 2 weeks
Trial: NCT02187614
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02187614
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01892306
Drug: Treatment as usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing optimized pharmacotherapy as delivered by treating psychiatrist
Trial: NCT03408340
Drug: Standard of Care Anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
Trial: NCT04184492
Drug: NovoMix® 30 Penfill®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biphasic insulin aspart 30 in doses 0.4 IU/kg
Trial: NCT02378805
Drug: Angiotensin-receptor blocker (ARB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observational study
Trial: NCT02378805
Drug: HMG-Coenzyme inhibitor (statin)
RxNorm normalized name: HMG CoA reductase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observational study
Trial: NCT02378805
Drug: Spironolactone or Finerenone
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: observational study
Trial: NCT03868540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03141554
Drug: 1% Betadine® PVP-I based mouth wash and gargle,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Betadine® PVP-I based mouth wash and gargle
Trial: NCT00612079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 4mg Placebo
Trial: NCT01160211
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
Trial: NCT04072380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets
Trial: NCT02664805
Drug: LEO 124249 ointment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ointment
Trial: NCT02664805
Drug: LEO 124249 ointment vehicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ointment vehicle
Trial: NCT02420665
Drug: Acetic Acid
RxNorm normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 - 5% added to cervix before visual inspection.
Trial: NCT04641754
Drug: WX-0593 Tablets
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, 60 mg→180mg, quaque die（QD）
Trial: NCT00349882
Drug: Marketed multipurpose disinfection regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02523274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable-based cellulose
Trial: NCT03786809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients of the placebo group will use placebo once a day for 28 days
Trial: NCT01832363
Drug: HXe MRI guided treatment sequence for BT
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
Trial: NCT00761150
Drug: ABT-712
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-712 extended-release tablet
Trial: NCT00761150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT02734290
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
Trial: NCT02424214
Drug: Ca Ionophore
RxNorm normalized name: iodophors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02184351
Drug: Mycelex® troches
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04763876
Drug: Ketorolac Injection 15 mg
RxNorm normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 15 mg ketorolac administered intramuscularly.
Trial: NCT04763876
Drug: Ketorolac Injection 60 mg
RxNorm normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 60 mg ketorolac administered intramuscularly.
Trial: NCT03018665
Drug: BIAsp30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection，fit dosage twice a day in three months
Trial: NCT03402620
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
Trial: NCT02354976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to Omega-3 carboxylic acids (olive oil)
Trial: NCT02354976
Drug: Omega-3 carboxylic acid
RxNorm normalized name: omega-3 carboxylic acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g administered as 4 x 1 g capsules
Trial: NCT02354976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to fenofibrate 200mg
Trial: NCT03002376
Drug: REGN2810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN2810 treatment
Trial: NCT04209218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml normal saline) is administered before anesthesia induction.
Trial: NCT00913250
Drug: Serum containing Avonex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
Trial: NCT00913250
Drug: Serum Free Avonex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
Trial: NCT03690141
Drug: eFT508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
Trial: NCT00084773
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01247896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose Placebo
Trial: NCT03963999
Drug: Contrast Enhanced Ultrasound (CEUS)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
Trial: NCT00773552
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab PO Qday x 90 days
Trial: NCT01857310
Drug: Placebo Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00353028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00993135
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00580333
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative: Given intravenously for four 2-week cycles
Trial: NCT00580333
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative: Given intravenously for four two-week cycles
Trial: NCT01931137
Drug: insulin 338 (GIPET I)
RxNorm normalized name: insulin isophane, human Injectable Suspension [Humulin I]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level of 8100 nmol will be orally administered as one tablet per dose.
Trial: NCT00267007
Drug: PROCRIT 40,000 IU QW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
Trial: NCT00267007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
Trial: NCT00423488
Drug: Simvastatin 20 mg
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 20-mg tablet, provided as open-label study treatment
Trial: NCT00972478
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00972478
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00423488
Drug: Simvastatin 20 mg
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 20-mg tablet, provided as blinded study treatment
Trial: NCT00056082
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib daily for 12 months
Trial: NCT02633761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
Trial: NCT03118765
Drug: GSP304 (tiotropium bromide) Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (QD) oral inhalation using a nebulizer
Trial: NCT03118765
Drug: GSP304 Placebo Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (QD) oral inhalation using a nebulizer
Trial: NCT03118765
Drug: Spiriva® Respimat® inhalation spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (QD) oral inhalation
Trial: NCT03398278
Drug: OXYCONTIN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally taking OXYCONTIN® 40mg in fast state
Trial: NCT02440100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo which will be given as oral suspension, once a day for 14 days
Trial: NCT00814125
Drug: Nolvadex placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00814125
Drug: Arimidex placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00307879
Drug: Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04749615
Drug: Saline Control Periarticular Injection (PAI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equal volume of saline will be used in place of analgesics used in PAI injections
Trial: NCT02127060
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for 1 month postoperative period, placebo medication administered orally to the patients.
Trial: NCT01235871
Drug: SB1578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAK2 Inhibitor
Trial: NCT01235871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm
Trial: NCT00000253
Drug: 10% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000253
Drug: 20% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000253
Drug: 30% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000253
Drug: 40% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006157
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02252497
Drug: Placebo comparator : physiologic serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours